The Premium Business Information Source™
Report title:
DAEWOONG PHARMACEUTICAL CO. LTD.-COMPANY INSIGHT
from
TF Market Research
25 page report published Jul 14, 2008
Price
$960.00
available for immediate download
This report is also available for purchase on a
per-page basis
.
Report Overview
Purchase by Section
Search Inside
...Daewoong Pharmaceutical Co. Ltd is a manufacturer engaged in the provision of pharmaceutical products. The company was founded in #### with a mission to provide treatment and sa tisfaction to patients and families with high quality drugs. Its vision is to be a global healthcare group leading improvement in the quality of life. Daewoong's core technology offers Wound Healing-EGF (Epidermal Growth Factor) stimulating the entire woun d healing process, biopharmaceuticals-e fficient manufacturing system utilizing animal cells, microbes and viral vectors, new pharmac euticals-excellent antibody screening and edymetox systems, formulation and drug delivery system-susta ined release of peptides; stabilization of moisture- sensitive molecules by using double layer/core tablet s and chemical synthesis- synthesizing and purifying techniques produce value-added products. Daewoong offers products in four categories which include: Biopharmaceutical, New Chemical Entity (NCE), Drug...
Source:
LIFE SCIENCE ANALYTICS
Author:
HARINATHA, G.
Company:
DAEWOONG PHARMACEUTICAL CO LTD
Geographic Regions:
ASIA, EASTERN ASIA, KOREA, REPUBLIC OF
Non-Billable Page Numbers:
2
Sections
Title
Starting Page
Number of Pages
Company Information
1
1
Daewoong Pharmaceutical Co. Ltd. [NonUS -- Symbol : Stock Code Number : 069620 (KOE)]
1
1
Formation Date: 1945
1
1
Business Summary
1
1
Product Glance
3
1
Trial Phase
3
1
No of Products
3
2
Diseasehub Classification
3
1
Disease Hub
4
1
Product Summary
4
1
Trial Phase Source Partner
4
2
Condition Treated
5
1
Products
5
1
Product Details
5
1
1. Perivar Disease Hub Description
5
1
Therapeutic Indication Current Trial Trial Details Last Updated
5
1
2. Smecta Disease Hub Description
6
1
Therapeutic Indication Drug Class Current Trial Trial Details Last Updated 3. Erdos Disease Hub Description
6
1
Therapeutic Indication Drug Class Current Trial Trial Details Last Updated 4. Tiropa Disease Hub Description
6
1
Therapeutic Indication Drug Class Current Trial Trial Details Last Updated 5. Asacol Disease Hub Description
6
1
Therapeutic Indication Drug Class Current Trial Trial Details Last Updated 6. Gasmotin Disease Hub Description
6
1
Therapeutic Indication Current Trial Trial Details
6
1
Last Updated Partnering Details
7
1
7. Tenstaten Disease Hub Description
7
1
Therapeutic Indication Drug Class Current Trial M Trial Details Last Updated 8. Dynacirc SRO Disease Hub Description
7
1
Therapeutic Indication Drug Class Current Trial Trial Details Last Updated 9. Olmetec Disease Hub Description
7
1
Therapeutic Indication Drug Class Current Trial M Trial Details Last Updated 10. Methycobal Disease Hub Description
7
1
Therapeutic Indication Current Trial Trial Details Last Updated 11. Gluriad Disease Hub Description
8
1
Therapeutic Indication Drug Class Current Trial Trial Details Last Updated 12. Diabex Disease Hub Description
8
1
Therapeutic Indication Drug Class Current Trial Trial Details Last Updated 13. Airtal Disease Hub Description
8
1
Therapeutic Indication Drug Class Current Trial Trial Details Last Updated 14. Fenopron Disease Hub Description
8
1
Therapeutic Indication Current Trial Trial Details Last Updated 15. Rize Disease Hub Description
8
1
Therapeutic Indication Current Trial Trial Details Last Updated 16. Gliatilin Disease Hub Description
9
1
Therapeutic Indication Current Trial Trial Details Last Updated 17. Chicclean Disease Hub Description
9
1
Therapeutic Indication Current Trial Trial Details Last Updated 18. Chicclean Disease Hub Description
9
1
Therapeutic Indication Current Trial Trial Details Last Updated 19. Easyef Disease Hub Description
9
1
Therapeutic Indication Drug Class Current Trial Trial Details Last Updated 20. Asacol Disease Hub Description
9
1
Therapeutic Indication Current Trial Trial Details
9
1
Last Updated Partnering Details
10
2
21. Olmetec Plus Disease Hub Description
10
1
Therapeutic Indication Drug Class Current Trial Trial Details
10
1
Last Updated 22. Lipice Disease Hub Description
10
1
Therapeutic Indication Current Trial Trial Details Last Updated 24. Botox Disease Hub Description
10
1
Therapeutic Indication Current Trial Trial Details Last Updated 25. Nicostop Disease Hub Description
10
1
Therapeutic Indication Drug Class
10
1
Current Trial Trial Details
11
1
Last Updated 26. Levulan PDT Disease Hub Description
11
1
Therapeutic Indication Current Trial Trial Details
11
1
27. Allelock Disease Hub Description
11
1
Therapeutic Indication
11
1
Current Trial Trial Details Last Updated 28. Ursa Disease Hub Description
12
1
Therapeutic Indication Liver Current Trial M Trial Details Last Updated 29. Ursa complex Disease Hub Description Ursa
12
1
Therapeutic Indication Current Trial Trial Details Last Updated 30. Plunazol Disease Hub Description
12
1
Therapeutic Indication Drug Class Current Trial Trial Details Last Updated 31. Caretropin Disease Hub Description
12
1
Therapeutic Indication Growth Drug Class Hormone Current Trial PA Trial Details Presently it Last Updated 5/14/2008 32. rh-EP
12
1
Therapeutic Indication Drug Class Current Trial
12
1
Trial Details Presently it is Last Updated 5/17/2008 33. Catrix wound dressing Disease Hub Dermatology Description Catrix Wou
13
1
Therapeutic Indication Current Trial Trial Details
13
1
Last Updated Partnering Details
13
1
34. Easyef Disease Hub Description
13
1
Therapeutic Indication Current Trial Trial Details Last Updated 35. Easyef Disease Hub Description
13
1
Therapeutic Indication Mucositis Current Trial II Trial Details Presently it is in Last Updated 5/17/2008 36. Tamsulosin SR D
13
1
Therapeutic Indication Benign Prostatic Current Trial I Trial Details Presently it is in Last Updated 5/15/2008 37. Doxazosin
14
1
Therapeutic Indication Current Trial Trial Details Last Updated 41. DWP418 Disease Hub Description
14
1
Therapeutic Indication Multiple Sclerosis Current Trial PC Trial Details Presently it is in Last Updated 5/11/2008 46. Phense
15
1
Therapeutic Indication Drug Class Current Trial Trial Details
15
3
Last Updated Partnering Details
18
1
47. Easyef Disease Hub Description
18
1
Therapeutic Indication Current Trial Trial Details Last Updated 48. Easyef Disease Hub Description
19
1
Therapeutic Indication Current Trial Trial Details Last Updated 49. DWP423 Disease Hub Description
19
1
Therapeutic Indication Infectious Current Trial NA Trial Details Presently it Last Updated 4/3/2007 50. DWP-404 / DWP40458 Di
19
1
Therapeutic Indication Current Trial Trial Details
19
1
Last Updated
19
1
Corporate Partners
20
1
Deal Category: Product Date Source
20
1
Partner
20
2
Management Profile
22
1
Yoon, Yeong Hwan -- Chairman
22
1
Yoon, Jae Seung -- Vice Chairman and Chief Executive Officer
22
1
Lee, Jong Wook -- Chief Executive Officer
22
1
Koh, Yea-Wook -- General manager, R&D Center
22
1
Choi, Soo Jin -- General Manager, R&D Center
22
1
Park, Jae Hong -- Managing Director
22
1
2/11/2008 -- Daewoong Pharmaceutical, selected as a distinguished company of favorable labor- management relations
23
1
10/6/2005 -- The Health and Welfare Committee Of The National Assembly Visited Daewoong Pharmaceutical Hyangnam Factory
23
1
9/21/2005 -- Making High Quality Drug-'Differentiated Purchasing System'
23
1
9/2/2005 -- Success Story Of Coenzyme Q10 Development
23
1
5/6/2005 -- Easyef (Ingredient: EGF) With Excellent Effect Upon Treatment Of Chronic Injury And Scar Inhibition
23
1
3/29/2005 -- Daewoong Pharmaceutical Implements SRM System As Strategic Advanced Purchase Infra
23
1
9/21/2004 -- New Concept Anti-wrinkle Cosmetics Containing EGF Was Approved
23
1
8/31/2005 -- Joint Research On Alternative Medicine To Therapeutic Antibodies With Scotch Haptogen
24
1
5/16/2005 -- Haptogen Announce Landmark Collaboration with DaeWoong Pharmaceuticals to Develop Novel Anti-infectives
24
1
3/25/2005 -- New And Excellent ARB Hypertension Therapy "Olmetec Plus" Was Released
24
1
12/22/2004 -- Lescarden Enters Into Distribution Agreement for Catrix Wound Dressing in Korea
24
1
1/23/2003 -- Tillotts Pharma License Out the Rights of Asacol in South-Korea
24
1
5/10/1999 -- Dainippon Licenses Gasmotin to Daewoong of South Korea
24
1
2/1/1992 -- Allelix Supplies Epidermal Growth Factor to Daewoong
24
1
Intellectual Property
25
1
12/11/2006 -- Moxicle Patented Core Tablet Manufacturing Technology
25
1
8/24/2004 -- Obtained Patent Related With Development Of Platelet Therapy
25
1
Product Update
25
1
5/15/2007 -- Eisai Submits Application for Gastroprokinetic Agent Gasmotin in Thailand
25
1
Regulatory
25
1
10/3/2007 -- DUSA's Levulan Kerastick Receives Marketing Approval in Korea
25
1
Enter the keyword(s) which you would like to search for within this document and click "Search"
TF Market Research
TF Market Research® reports contain in-depth primary research and statistics, market trends, forecasts, segment analysis and much more from over 100 top consulting, market research and business publishing sources. The service is updated daily.
Price: $960.00
Questions about
this research?
Send to a friend